Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

buir.contributor.authorÖzçelik, Tayfun
buir.contributor.orcidÖzçelik,Tayfun|0000-0001-5937-1082
dc.citation.epageeabp8966-18en_US
dc.citation.issueNumber90
dc.citation.spageeabp8966-1
dc.citation.volumeNumber8
dc.contributor.authorBastard, P.
dc.contributor.authorVazquez, S. E.
dc.contributor.authorLiu, J.
dc.contributor.authorLaurie, M. T.
dc.contributor.authorWang, C. Y.
dc.contributor.authorGervais, A.
dc.contributor.authorVoyer, T. L.
dc.contributor.authorBizien, L.
dc.contributor.authorZamecnik, C.
dc.contributor.authorPhilippot, Q.
dc.contributor.authorRosain, J.
dc.contributor.authorCatherinot, E.
dc.contributor.authorWillmore, A.
dc.contributor.authorMitchell, A. M.
dc.contributor.authorBair, R.
dc.contributor.authorGarçon, P.
dc.contributor.authorKenney, H.
dc.contributor.authorFekkar, A.
dc.contributor.authorSalagianni, M.
dc.contributor.authorPoulakou, G.
dc.contributor.authorSiouti, E.
dc.contributor.authorSahanic, S.
dc.contributor.authorTancevski, I.
dc.contributor.authorWeiss, G.
dc.contributor.authorNagl, L
dc.contributor.authorManry, J.
dc.contributor.authorDuvlis, S.
dc.contributor.authorArroyo-Sánchez, D.
dc.contributor.authorArtal, E. P.
dc.contributor.authorRubio, L.
dc.contributor.authorPerani, C.
dc.contributor.authorBezzi, M.
dc.contributor.authorSottini, A.
dc.contributor.authorQuaresima, V.
dc.contributor.authorRoussel, L.
dc.contributor.authorVinh, D. C.
dc.contributor.authorReyes, L. F.
dc.contributor.authorGarzaro, M.
dc.contributor.authorHatipoglu, N.
dc.contributor.authorBoutboul, D.
dc.contributor.authorTandjaoui-Lambiotte, Y.
dc.contributor.authorBorghesi, A.
dc.contributor.authorAliberti, A.
dc.contributor.authorCassaniti, I.
dc.contributor.authorVenet, F.
dc.contributor.authorMonneret, G.
dc.contributor.authorHalwani, R.
dc.contributor.authorSharif-Askari, N. S.
dc.contributor.authorDanielson, J.
dc.contributor.authorBurrel, S.
dc.contributor.authorMorbieu, C.
dc.contributor.authorStepanovskyy, Y.
dc.contributor.authorBondarenko, A.
dc.contributor.authorVolokha, A.
dc.contributor.authorBoyarchuk, O.
dc.contributor.authorGagro, A.
dc.contributor.authorNeuville, M.
dc.contributor.authorNeven, B.
dc.contributor.authorKeles, S.
dc.contributor.authorHernu, R.
dc.contributor.authorBal, A.
dc.contributor.authorNovelli, A.
dc.contributor.authorNovelli, G.
dc.contributor.authorSaker, K.
dc.contributor.authorAilioaie, O.
dc.contributor.authorAntolí, A.
dc.contributor.authorJeziorski, E.
dc.contributor.authorRocamora-Blanch, G.
dc.contributor.authorTeixeira, C.
dc.contributor.authorDelaunay, C.
dc.contributor.authorLhuillier, M.
dc.contributor.authorTurnier, P. L.
dc.contributor.authorZhang, Y.
dc.contributor.authorMahevas, M.
dc.contributor.authorPan-Hammarström, Q.
dc.contributor.authorAbolhassani, H.
dc.contributor.authorBompoil, T.
dc.contributor.authorDorgham, K.
dc.contributor.authorConsortium, C.
dc.contributor.authorGroup, F.
dc.contributor.authorConsortium, C.
dc.contributor.authorGorochov, G.
dc.contributor.authorLaouenan, C.
dc.contributor.authorRodríguez-Gallego, C.
dc.contributor.authorNg, L. F. P.
dc.contributor.authorRenia, L.
dc.contributor.authorPujol, A.
dc.contributor.authorBelot, A.
dc.contributor.authorRaffi, F.
dc.contributor.authorAllende, L. M.
dc.contributor.authorMartinez-Picado, J.
dc.contributor.authorÖzçelik, Tayfun
dc.contributor.authorImberti, L.
dc.contributor.authorNotarangelo, L. D.
dc.contributor.authorTroya, J.
dc.contributor.authorSolanich, X.
dc.contributor.authorZhang, S.
dc.contributor.authorPuel, A.
dc.contributor.authorWilson, M. R.
dc.contributor.authorTrouillet-Assant, S.
dc.contributor.authorAbel, L.
dc.contributor.authorJouanguy, E.
dc.contributor.authorYe, C. J.
dc.contributor.authorCobat, A.
dc.contributor.authorThompson, L. M.
dc.contributor.authorAndreakos, E.
dc.contributor.authorZhang, Q.
dc.contributor.authorAnderson, M. S.
dc.contributor.authorCasanova, J.
dc.contributor.authorDeRisi, J. L.
dc.date.accessioned2024-03-11T10:35:24Z
dc.date.available2024-03-11T10:35:24Z
dc.date.issued2022-06-14
dc.departmentDepartment of Molecular Biology and Genetics
dc.description.abstractLife-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.
dc.identifier.doi10.1126/sciimmunol.abp8966
dc.identifier.eissn2470-9468
dc.identifier.urihttps://hdl.handle.net/11693/114497
dc.language.isoen
dc.publisherAmerican Association for the Advancement of Science (AAAS)
dc.relation.isversionofhttps://dx.doi.org/10.1126/sciimmunol.abp8966
dc.rightsCC BY 4.0 DEED (Attribution 4.0 International)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.source.titleScience Immunology
dc.titleVaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Vaccine_breakthrough_hypoxemic_COVID-19_pneumonia_in_patients_with_auto-Abs_neutralizing_type_I_IFNs.pdf
Size:
797.9 KB
Format:
Adobe Portable Document Format